Major Cardiovascular Player Acquires HuaYi ShengJie for RMB 1.87B; Shimaa Healthcare Strategically Invests in Peking University-Spinoff Ocular Gene Therapy Firm

1.87 Billion, Major Acquisition by Leading Domestic Cardiovascular Company

On May 22, 2026, Hong Kong-listed Lifetech Scientific announced its proposed acquisition of approximately 96.46% equity stake in Starway Medical for around RMB 1.8733 billion, with an overall agreed transaction value of approximately RMB 1.942 billion. The deal involves no cash payment and will be entirely settled through the issuance of convertible bonds as full consideration. The seller is ultimately wholly owned by Hillhouse Capital. This means Hillhouse Capital will act as both the seller and a significant shareholder of Lifetech Scientific, potentially even becoming its largest shareholder. This marks Hillhouse Capital's second follow-on investment in Lifetech Scientific within six years. (Source: Sina Finance)

C-MER Medical Takes Strategic Stake in Peking University-Affiliated Eye Gene Therapy Company

C-MER Healthcare (3309.HK) plans to lead the Series B financing round for Beijing Zhongyin Technology with an investment of approximately RMB 110 million, acquiring a 10.23% stake to become its second-largest shareholder. Zhongyin Technology is a leading Chinese ocular gene therapy enterprise incubated by Peking University Third Hospital. Its core product, ZVS101e, targets Bietti crystalline dystrophy (BCD), a rare eye disease with no available treatment. It has completed Phase III clinical trials in China, received U.S. FDA approval to conduct Phase III clinical trials, and was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA in 2024, making it the first Chinese ocular gene therapy product to receive this certification. (Source: Sina Finance)

Zai Lab Announces Senior Management Team Changes, President and COO Departs

On May 21, Zai Lab announced adjustments to its senior management team, aimed at further enhancing operational performance and efficiency. As part of this adjustment, the board of directors decided that President and Chief Operating Officer Josh Smiley will step down from his positions at the company effective May 22 (Friday). Dr. Ying Du, Founder, Chairman, and Chief Executive Officer of Zai Lab, stated: "I would like to thank Josh for his contributions to the company over the past three and a half years, and wish him all the best in the future." (Source: VCBeat)

Dashenlin, Acquires Well-Known Chain Stores

Dashenlin spent RMB 51.73 million to acquire 100% equity in Medbanks Zhihe Technology (Guangzhou), a subsidiary of Medbanks, along with full ownership of two affiliated companies, Siweite and Beijing Renbo. Medbanks Zhihe Technology (Guangzhou) operates four pharmacies and supply chain businesses in Beijing and Hubei, recorded revenue of RMB 485 million in 2025, and held net assets of RMB 15.0797 million as of March 2026. (Source: VBData)

ROBO Medical Completes Tens of Millions of RMB in Series B+ Funding

Recently, ROBO Medical, the first company globally to receive regulatory approval for a gastrointestinal endoscopic surgical robot, officially announced the successful completion of a financing round totaling tens of millions of RMB. This round was led by Shuimu Capital, with industry investor Boyue Tiancheng participating as a co-investor, and Siche Consulting serving as the long-term exclusive financial advisor. (Source: VBData)

Sibolicon Secures Nearly 100 Million RMB in Series A Funding

Recently, Sichuan Nuohong Huikang Biotechnology Co., Ltd. (brand name: Sbolikang), a company specializing in the R&D of upstream reagents and CRDMO services in the CGT (cell and gene therapy) sector, has completed a Series A financing round of nearly RMB 100 million. This round was led by Jincheng Fund under Luzhou Development Holding Group, with follow-on investment from Zero2IPO Capital, and increased investment from existing shareholder Heli Investment. Shengkeji Capital served as the exclusive financial advisor for Sbolikang in this transaction. (Source: VBData)

Xinhong Life Secures Series A Financing

Recently, Xinhong Life completed a Series A financing round of tens of millions of RMB, exclusively led by Yifeng Zhuohua Fund, a renowned institution focused on the healthcare industry. This capital injection will further accelerate the commercialization of Xinhong Life's innovative ultrasound energy devices, consolidate the core technological barriers of drug-ultrasound synergy, and comprehensively build an innovative ultrasound ecosystem encompassing “ultrasound energy, drug-ultrasound synergy, and precision diagnosis and treatment.” (Source: VCBeat)

Fulian Technology Announces Completion of Over RMB 1 Billion Financing

May 19, 2026, SUZHOU, China / GEMBLOUX, Belgium – RadioLink Therapeutics Co., Ltd. (hereinafter referred to as “RadioLink Therapeutics”), a fully integrated, clinical-stage international radiopharmaceutical therapeutics company, today announced the completion of a financing round exceeding RMB 1 billion, including approximately RMB 750 million in Series D equity financing and RMB 270 million in debt financing. (Source: VCBeat)

State Council: Step Up Implementation of Policy on Enrolling Residence Permit Holders in Basic Medical Insurance for Urban and Rural Residents

May 22: The State Council has issued the *Implementation Opinions on Providing Basic Public Services Based on Place of Permanent Residence*. It proposes strengthening basic medical security in the place of permanent residence. Efforts will be intensified to implement policies allowing residence permit holders to enroll in the Basic Medical Insurance for Urban and Rural Residents. Mega and super-large cities, as well as other municipalities, must effectively safeguard the rights of non-locally registered primary and secondary school students, preschool children, and others to participate in the Basic Medical Insurance for Urban and Rural Residents in their place of permanent residence. Local governments shall provide financial subsidies to insured individuals holding residence permits at the same standard as for locally registered residents, thereby consolidating and expanding insurance coverage. Management and services for the direct settlement of cross-regional medical expenses will be strengthened to enhance the accessibility and convenience of registration management and settlement reimbursement for cross-regional medical treatment. (Source: Sina Finance)